This is an exciting time for the treatment of amyloid light-chain (AL) amyloidosis, with a number of novel therapies on the horizon. In this interview, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the novel agents currently in clinical trials, which can target the amyloid deposits characterizing the disease. Dr Merlini highlights NEOD001 (Phase III VITAL study; NCT02312206) and the combination of CPHPC and anti-serum amyloid P component antibodies (NCT01777243). This video was recorded at the 1st European Myeloma Network Meeting (EMN), in Turin, Italy.
New antibody treatments for AL amyloidosis
